SCHEMBL15469489

SCHEMBL15469489

COc1cnc2c(c1)OCC[C@]2(N)c1ccc(C)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 13/20 0.36
APP P05067 5/20 0.36
BACE2 Q9Y5Z0 6/20 0.34
SYK P43405 1/20 0.31
KDM4E B2RXH2 1/20 0.31
JAK2 O60674 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
MET P08581 1/20 0.30
AKR1B10 O60218 1/20 0.30
AKR1C4 P17516 1/20 0.30
AKR1C3 P42330 1/20 0.30
AKR1C2 P52895 1/20 0.30
AKR1C1 Q04828 1/20 0.30
CTSD P07339 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15469465 0.86 BACE1 (0.32) BACE1APPAKR1B10AKR1C4AKR1C3
SCHEMBL15469480 0.86 BACE1 (0.34) BACE1APPAKR1B10AKR1C4AKR1C3
SCHEMBL15469472 0.85 MAP3K14 (0.36) BACE1APPBACE2AKR1B10AKR1C4
SCHEMBL15467834 0.84 PDE2A (0.37) BACE1APPBACE2
SCHEMBL15467833 0.84 PDE2A (0.37) BACE1APPBACE2
SCHEMBL15469386 0.80 TRPM8 (0.33) BACE1APPAKR1B10AKR1C4AKR1C3
SCHEMBL15469414 0.80 TRPM8 (0.33) BACE1APPAKR1B10AKR1C4AKR1C3
SCHEMBL15469483 0.79 SCN9A (0.36) BACE1APPAKR1B10AKR1C4AKR1C3
SCHEMBL15469495 0.76 BACE1 (0.32) BACE1APPAKR1B10AKR1C4AKR1C3
SCHEMBL15469477 0.75 AKR1B10 (0.35) BACE1APPAKR1B10AKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 BACE1 2029/4885APP 1623/4885BACE2 2642/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 BACE1 2029/4885APP 1623/4885BACE2 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.